---
title: "Oruka Therapeutics Drops 7.9% After Stock Offering"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284614293.md"
description: "Oruka Therapeutics (ORKA.US) current price $68.125, down 7.93% for the day, intraday drop below 8%, market capitalization $3.41 billion. The company recently announced an expansion of its underwritten public offering to $700 million, putting short-term pressure on the market. As a biopharmaceutical company, institutions are cautiously responding to the adjustment of the capital structure, and there are currently no other significant catalysts"
datetime: "2026-04-29T16:42:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284614293.md)
  - [en](https://longbridge.com/en/news/284614293.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284614293.md)
---

# Oruka Therapeutics Drops 7.9% After Stock Offering

Oruka Therapeutics (ORKA.US) is trading at $68.125, down **7.93%** intraday, falling more than 8% during the session, with a market cap of $3.41 billion.

The stock faced selling pressure after the company announced an upsized $700 million underwritten public offering. As a biopharma company, investor sentiment is cautious amid share dilution concerns, with no major other catalysts reported recently.

\---

### Related Stocks

- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)